JP7427212B2 - 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 - Google Patents

非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 Download PDF

Info

Publication number
JP7427212B2
JP7427212B2 JP2018560887A JP2018560887A JP7427212B2 JP 7427212 B2 JP7427212 B2 JP 7427212B2 JP 2018560887 A JP2018560887 A JP 2018560887A JP 2018560887 A JP2018560887 A JP 2018560887A JP 7427212 B2 JP7427212 B2 JP 7427212B2
Authority
JP
Japan
Prior art keywords
bvd
braf
cells
inhibitor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018560887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519519A5 (https=
JP2019519519A (ja
Inventor
サウラブ サハ，
ディーン ウェルシュ，
ゲイリー デクレッセンゾ，
ジェフリー ジェイムズ ロワ，
Original Assignee
バイオメッド バレー ディスカバリーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオメッド バレー ディスカバリーズ，インコーポレイティド filed Critical バイオメッド バレー ディスカバリーズ，インコーポレイティド
Publication of JP2019519519A publication Critical patent/JP2019519519A/ja
Publication of JP2019519519A5 publication Critical patent/JP2019519519A5/ja
Priority to JP2021214205A priority Critical patent/JP2022034068A/ja
Application granted granted Critical
Publication of JP7427212B2 publication Critical patent/JP7427212B2/ja
Priority to JP2024108968A priority patent/JP2024133638A/ja
Priority to JP2026001737A priority patent/JP2026053745A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2018560887A 2013-12-20 2017-05-22 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 Active JP7427212B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021214205A JP2022034068A (ja) 2013-12-20 2021-12-28 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
JP2024108968A JP2024133638A (ja) 2013-12-20 2024-07-05 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
JP2026001737A JP2026053745A (ja) 2013-12-20 2026-01-07 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361919551P 2013-12-20 2013-12-20
US15/161,137 US20160317519A1 (en) 2013-12-20 2016-05-20 Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
US15/161,137 2016-05-20
PCT/US2017/033843 WO2017201532A1 (en) 2013-12-20 2017-05-22 Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021214205A Division JP2022034068A (ja) 2013-12-20 2021-12-28 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2019519519A JP2019519519A (ja) 2019-07-11
JP2019519519A5 JP2019519519A5 (https=) 2020-06-25
JP7427212B2 true JP7427212B2 (ja) 2024-02-05

Family

ID=53403903

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018560887A Active JP7427212B2 (ja) 2013-12-20 2017-05-22 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
JP2021214205A Withdrawn JP2022034068A (ja) 2013-12-20 2021-12-28 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
JP2024108968A Pending JP2024133638A (ja) 2013-12-20 2024-07-05 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
JP2026001737A Pending JP2026053745A (ja) 2013-12-20 2026-01-07 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021214205A Withdrawn JP2022034068A (ja) 2013-12-20 2021-12-28 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
JP2024108968A Pending JP2024133638A (ja) 2013-12-20 2024-07-05 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
JP2026001737A Pending JP2026053745A (ja) 2013-12-20 2026-01-07 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物

Country Status (16)

Country Link
US (5) US20160317519A1 (https=)
EP (2) EP3458056B1 (https=)
JP (4) JP7427212B2 (https=)
KR (2) KR20190009804A (https=)
CN (2) CN109475541A (https=)
AU (3) AU2017267804B2 (https=)
BR (1) BR112018073786A2 (https=)
CA (1) CA3024703A1 (https=)
CL (1) CL2018003282A1 (https=)
ES (1) ES3056393T3 (https=)
IL (2) IL294056A (https=)
MX (2) MX392121B (https=)
RU (1) RU2018145048A (https=)
SG (1) SG11201810287RA (https=)
WO (2) WO2015095842A2 (https=)
ZA (2) ZA201808480B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
BR112018012255A2 (pt) * 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
WO2017180581A1 (en) * 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2017180817A1 (en) * 2016-04-15 2017-10-19 Musc Foundation For Research Development Treatment of septicemia and ards with erk inhibitors
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
AU2018269982B2 (en) * 2017-05-16 2024-06-13 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical BRAF mutations
WO2019084459A1 (en) * 2017-10-26 2019-05-02 Xynomic Pharmaceuticals, Inc. CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR
CN112218634A (zh) * 2018-04-09 2021-01-12 G1治疗公司 具有驱动致癌突变的癌症的治疗
CN110656172A (zh) * 2019-01-14 2020-01-07 南方医科大学珠江医院 一种预测小细胞肺癌对ep化疗方案敏感性的分子标志物及试剂盒
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114981298B (zh) * 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
KR102697384B1 (ko) * 2022-01-13 2024-08-22 팔라디바이오텍 주식회사 리셉터 티로신 키나제 저해제를 탐색하는 방법
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
WO2026020045A1 (en) * 2024-07-17 2026-01-22 4M Therapeutics Inc. N-desmethyl ruboxistaurin as a rsk inhibitor for therapeutic use
WO2026030476A1 (en) * 2024-07-30 2026-02-05 Genentech, Inc. Precision medicine for optimal dosage of combined therapies systems and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095833A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers
JP2015531763A (ja) 2012-08-17 2015-11-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
JP2016513097A (ja) 2013-02-11 2016-05-12 アブラクシス バイオサイエンス， エルエルシー メラノーマの治療方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE220114T1 (de) 1993-03-19 2002-07-15 Sequenom Inc Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
GB0320059D0 (en) 2003-08-27 2003-10-01 Solexa Ltd A method of sequencing
LT3305776T (lt) * 2004-05-14 2020-01-10 Vertex Pharmaceuticals Incorporated Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
CA2609387A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
WO2010062546A1 (en) 2008-10-27 2010-06-03 Qiagen Gaithersburg Inc. Fast results hybrid capture assay on an automated platform
KR20120046018A (ko) 2010-10-04 2012-05-09 삼성테크윈 주식회사 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출
WO2012125848A2 (en) 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
CA3240745A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
WO2015095834A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors
JP6543612B2 (ja) * 2014-03-04 2019-07-10 浩文 山本 大腸癌の治療剤、及び大腸癌患者の予後の予測方法
WO2016025649A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a dot1l inhibitor and related methods
AU2016211246B2 (en) * 2015-01-30 2020-08-27 Biomed Valley Discoveries, Inc. Crystalline forms of C21H22CI2N4O2
JP7180977B2 (ja) * 2015-01-30 2022-11-30 バイオメッド バレー ディスカバリーズ，インコーポレイティド 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015531763A (ja) 2012-08-17 2015-11-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法
JP2016513097A (ja) 2013-02-11 2016-05-12 アブラクシス バイオサイエンス， エルエルシー メラノーマの治療方法
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
WO2015095833A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
「Ｄｏｓｅ ｅｓｃａｌａｔｉｏｎ ｓｔａｇｅ ｏｆ ａ ｆｉｒｓｔ－ｉｎ－ｃｌａｓｓ ｐｈａｓｅ Ｉ ｓｔｕｄｙ ｏｆ ｔｈｅ ｎｏｖｅｌ ｏｒａｌ ＥＲＫ １／２ ｋｉｎａｓｅ ｉｎｈｉｂｉｔｏｒ ＢＶＤ－５２３（ｕｌｉｘｅｒｔｉｎｉｂ） ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ａｄｖａｎｃｅｄ ｓｏｌｉｄ ｔｕｍｏｒｓ．」， Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｏｎｃｏｌｏｇｙ， Ｖｏｌ．３３， Ｉｓｓｕｅ．１５＿ｓｕｐｐｌ， Ｐｕｂｌｉｓｈｅｄ ｏｎｌｉｎｅ Ｍａｙ ２０ ２０１５， 「Ａｂｓｔｒａｃｔ ２５０６」， ＤＯＩ：１０．１２００／ｊｃｏ．２０１５．３３．１５＿ｓｕｐｐｌ．２５０６， ｈｔｔｐｓ：／／ａｓｃｏｐｕｂｓ．ｏｒｇ／ｄｏｉ／１０．１２００／ｊｃｏ．２０１５．３３．１５＿ｓｕｐｐｌ．２５０６
Ｈｉｓｔｏｒｙ ｏｆ Ｃｈａｎｇｅｓ ｆｏｒ Ｓｔｕｄｙ： ＮＣＴ０１７８１４２９， 「Ｊｕｌｙ．３１．２０１４ Ｃｏｎｔａｃｔｓ／Ｌｏｃａｔｉｏｎｓ ａｎｄ Ｓｔｕｄｙ Ｓｔａｔｕｓ」， ｐ．１－５
Ｐｅｅｒ Ｊ， ２０１３， ＤＯＩ １０．７７１７／ｐｅｅｒｊ．１０４， ｐ．１－１６
Ｐｉｇｍｅｎｔ Ｃｅｌｌ Ｍｅｌａｎｏｍａ Ｒｅｓ．， ２０１３， Ｖｏｌ．２６， Ｎｏ．６ ｄｏｉ：１０．１１１１／ｐｃｍｒ．１２１４８．，Ｐａｇｅ １－１３

Also Published As

Publication number Publication date
MX2022005473A (es) 2022-06-02
IL263108B (en) 2022-08-01
US20220117950A1 (en) 2022-04-21
WO2015095842A3 (en) 2015-08-20
AU2023204587A1 (en) 2023-08-17
US20210038587A1 (en) 2021-02-11
AU2023204587B2 (en) 2025-04-03
US12599593B2 (en) 2026-04-14
EP3458056B1 (en) 2025-10-15
SG11201810287RA (en) 2018-12-28
US10881646B2 (en) 2021-01-05
CL2018003282A1 (es) 2019-10-18
ZA202007734B (en) 2022-04-28
CN109475541A (zh) 2019-03-15
EP4653055A2 (en) 2025-11-26
MX2018014231A (es) 2019-05-15
US20190201387A1 (en) 2019-07-04
MX392121B (es) 2025-03-21
AU2017267804A1 (en) 2019-01-17
EP3458056A4 (en) 2020-01-08
ZA201808480B (en) 2022-04-28
BR112018073786A2 (pt) 2019-02-26
ES3056393T3 (en) 2026-02-20
IL294056A (en) 2022-08-01
IL263108A (en) 2018-12-31
JP2024133638A (ja) 2024-10-02
KR20230025941A (ko) 2023-02-23
US11246859B2 (en) 2022-02-15
CN120501744A (zh) 2025-08-19
CA3024703A1 (en) 2017-11-23
JP2019519519A (ja) 2019-07-11
AU2017267804B2 (en) 2023-04-27
EP3458056A1 (en) 2019-03-27
JP2026053745A (ja) 2026-03-25
JP2022034068A (ja) 2022-03-02
EP4653055A3 (en) 2026-03-18
RU2018145048A (ru) 2020-06-22
AU2025204585A1 (en) 2025-07-10
US20180104228A1 (en) 2018-04-19
US20160317519A1 (en) 2016-11-03
WO2017201532A1 (en) 2017-11-23
WO2015095842A2 (en) 2015-06-25
KR20190009804A (ko) 2019-01-29

Similar Documents

Publication Publication Date Title
JP7427212B2 (ja) 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
US20240374604A1 (en) Cancer treatments using combinations of cdk and erk inhibitors
JP6678585B2 (ja) Ｅｒｋ阻害剤およびｒａｆ阻害剤の組み合わせを使用するがん処置
JP6727127B2 (ja) Ｐｉ３ｋ／ａｋｔシグナル経路阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置
CN116036278B (zh) 用于治疗具有非典型braf突变的癌症的组合物和方法
JP6678583B2 (ja) ２型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを用いるがん処置
JP2017502016A (ja) １型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがんの処置
HK40086947B (zh) 用於治疗具有非典型braf突变的癌症的组合物和方法
HK40086947A (zh) 用於治疗具有非典型braf突变的癌症的组合物和方法
HK1231779B (zh) 使用erk和raf抑制剂的组合的癌症治疗
HK1231779A1 (en) Cancer treatment using combinations of erk and raf inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211228

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211228

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220113

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220215

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220216

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220401

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220405

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230915

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240117

R150 Certificate of patent or registration of utility model

Ref document number: 7427212

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150